{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-102134","form_type":"8-K","ticker":"ESLA","cik":"0001844417","company_name":"Estrella Immunopharma, Inc.","filed_at":"2024-11-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.998117+00:00","generated_at":"2026-05-29T19:07:08.442427+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Estrella Immunopharma receives Nasdaq deficiency notices for low equity and low bid price","bullets":["Stockholders' equity of $746,286 as of Sep 30, 2024, below Nasdaq's $2.5M minimum.","Has until Jan 3, 2025 to submit a compliance plan; Nasdaq may grant up to 180-day extension.","Separate bid price deficiency: common stock below $1.00 for 30 consecutive business days; cure period until May 19, 2025.","Both deficiencies have no immediate effect on listing, but failure to regain compliance could lead to delisting.","Company evaluating options to regain compliance; no assurance of success."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-102134","json":"https://secwatch.observer/filing/0001213900-24-102134.json","markdown":"https://secwatch.observer/filing/0001213900-24-102134.md","text":"https://secwatch.observer/filing/0001213900-24-102134.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1844417/000121390024102134/0001213900-24-102134-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1844417/000121390024102134/ea0222513-8k_estrella.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T19:07:08.442427+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}